118 related articles for article (PubMed ID: 37659683)
21. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
Zhang C; Wang M; Shi C; Shi F; Pei C
Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351
[TBL] [Abstract][Full Text] [Related]
22. Sanguinarine enhances cisplatin sensitivity via glutathione depletion in cisplatin-resistant ovarian cancer (A2780) cells.
Sarkhosh-Inanlou R; Molaparast M; Mohammadzadeh A; Shafiei-Irannejad V
Chem Biol Drug Des; 2020 Feb; 95(2):215-223. PubMed ID: 31512406
[TBL] [Abstract][Full Text] [Related]
23. Knock-down of superoxide dismutase 1 sensitizes cisplatin-resistant human ovarian cancer cells.
Kim JW; Sahm H; You J; Wang M
Anticancer Res; 2010 Jul; 30(7):2577-81. PubMed ID: 20682985
[TBL] [Abstract][Full Text] [Related]
24. Malformin-A1 (MA1) Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin-Induced Apoptosis.
Abdullah N; Tamimi Y; Dobretsov S; Balushi NA; Alshekaili J; Al Balushi H; Al Kindi M; Hassan SI; Bahlani SA; Tsang BK; Burney IA
Molecules; 2021 Jun; 26(12):. PubMed ID: 34199287
[TBL] [Abstract][Full Text] [Related]
25. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
26. MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.
Rao YM; Shi HR; Ji M; Chen CH
J Huazhong Univ Sci Technolog Med Sci; 2013 Aug; 33(4):567-572. PubMed ID: 23904379
[TBL] [Abstract][Full Text] [Related]
27. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M
J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296
[TBL] [Abstract][Full Text] [Related]
28. [Role of apoptosis-associated genes and caspase-3 in cisplatin-resistant human ovarian cancer cell lines].
Yang XK; Xing H; Zheng F; Gao QL; Wang W; Lu YP; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2003 Mar; 38(3):158-61. PubMed ID: 12816691
[TBL] [Abstract][Full Text] [Related]
29. Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer.
Yang X; Zheng F; Xing H; Gao Q; Wei W; Lu Y; Wang S; Zhou J; Hu W; Ma D
J Cancer Res Clin Oncol; 2004 Jul; 130(7):423-8. PubMed ID: 15156398
[TBL] [Abstract][Full Text] [Related]
30. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
Ma JJ; Chen BL; Xin XY
Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
[TBL] [Abstract][Full Text] [Related]
31. The effect of sodium butyrate and cisplatin on expression of EMT markers.
Mrkvicova A; Chmelarova M; Peterova E; Havelek R; Baranova I; Kazimirova P; Rudolf E; Rezacova M
PLoS One; 2019; 14(1):e0210889. PubMed ID: 30653577
[TBL] [Abstract][Full Text] [Related]
32. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
33. Targeting superoxide dismutase 1 to overcome cisplatin resistance in human ovarian cancer.
Brown DP; Chin-Sinex H; Nie B; Mendonca MS; Wang M
Cancer Chemother Pharmacol; 2009 Mar; 63(4):723-30. PubMed ID: 18622615
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
35. Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion.
Wang H; Luo Y; Qiao T; Wu Z; Huang Z
J Ovarian Res; 2018 Nov; 11(1):93. PubMed ID: 30454003
[TBL] [Abstract][Full Text] [Related]
36. Restoration of microRNA-708 sensitizes ovarian cancer cells to cisplatin via IGF2BP1/Akt pathway.
Qin X; Sun L; Wang J
Cell Biol Int; 2017 Oct; 41(10):1110-1118. PubMed ID: 28685895
[TBL] [Abstract][Full Text] [Related]
37. Silencing Wnt2B by siRNA interference inhibits metastasis and enhances chemotherapy sensitivity in ovarian cancer.
Wang H; Fan L; Xia X; Rao Y; Ma Q; Yang J; Lu Y; Wang C; Ma D; Huang X
Int J Gynecol Cancer; 2012 Jun; 22(5):755-61. PubMed ID: 22635028
[TBL] [Abstract][Full Text] [Related]
38. Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving.
Wang DY; Li N; Cui YL
Cancer Res Treat; 2020 Jul; 52(3):798-814. PubMed ID: 32124583
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin-induced caspase activation mediates PTEN cleavage in ovarian cancer cells: a potential mechanism of chemoresistance.
Singh M; Chaudhry P; Fabi F; Asselin E
BMC Cancer; 2013 May; 13():233. PubMed ID: 23663432
[TBL] [Abstract][Full Text] [Related]
40. Relationship between p-cofilin and cisplatin resistance in patients with ovarian cancer and the role of p-cofilin in prognosis.
Qin Y; Li W; Long Y; Zhan Z
Cancer Biomark; 2019; 24(4):469-475. PubMed ID: 30932883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
